Avinger to Announce Fourth Quarter and Full Year 2018 Financial Results on March 6, 2019
February 28 2019 - 8:30AM
Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device
company marketing the first and only intravascular image-guided,
catheter-based system for diagnosis and treatment of patients with
Peripheral Artery Disease (PAD), today announced that it will
release its financial results for the fourth quarter and full year
2018 after the close of trading on Wednesday, March 6, 2019. The
Company will host a conference call beginning at 1:30pm PT/4:30pm
ET.
Individuals interested in listening to the conference call may
do so by dialing 877-407-9205 for domestic callers or
+1-201-689-8054 for international callers. To listen to a live
webcast, please visit http://www.avinger.com and select Investor
Relations.
A replay of the call will be available beginning March 6, 2019
at approximately 7:30pm PT/10:30pm ET through March 13, 2019. To
access the replay, dial 877-481-4010 and reference Conference ID:
44910. The webcast will also be available on Avinger's website
following completion of the call at www.avinger.com.
About Avinger, Inc.Avinger is a
commercial-stage medical device company that designs and develops
the first-ever image-guided, catheter-based system that diagnoses
and treats patients with peripheral artery disease (PAD). PAD is
estimated to affect over 12 million people in the U.S. and over 200
million worldwide. Avinger is dedicated to radically changing the
way vascular disease is treated through its Lumivascular platform,
which currently consists of the Lightbox imaging console, the
Ocelot family of chronic total occlusion (CTO) catheters, and the
Pantheris® family of atherectomy devices. Avinger is based in
Redwood City, California. For more information, please
visit www.avinger.com.
Forward-Looking StatementsThis news release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 and the Private Securities Litigation Reform
Act of 1995. These forward-looking statements include statements
regarding the anticipated closing of the offering and use of
proceeds from the offering. Such statements are based on current
assumptions that involve risks and uncertainties that could cause
actual outcomes and results to differ materially. These risks and
uncertainties, many of which are beyond our control, include our
dependency on a limited number of products; our ability to
demonstrate the benefits of our Lumivascular platform; the resource
requirements related to Pantheris; the outcome of clinical trial
results; potential exposure to third-party product liability,
intellectual property and other litigation; lack of long-term data
demonstrating the safety and efficacy of our Lumivascular platform
products; experiences of high-volume users of our products may lead
to better patient outcomes than those of physicians that are less
proficient; reliance on third-party vendors; dependency on
physician adoption; reliance on key personnel; and requirements to
obtain regulatory approval to commercialize our products; as well
as the other risks described in the section entitled "Risk Factors"
and elsewhere in our quarterly Form 10-Q filing made with the
Securities and Exchange Commission on November 13, 2018. These
forward-looking statements speak only as of the date hereof and
should not be unduly relied upon. Avinger disclaims any obligation
to update these forward-looking statements.
Investor Contact:Mark WeinswigChief Financial
OfficerAvinger, Inc.(650) 241-7916ir@avinger.com
Matt KrepsDarrow Associates Investor Relations(214)
597-8200mkreps@darrowir.com
Avinger (NASDAQ:AVGR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avinger (NASDAQ:AVGR)
Historical Stock Chart
From Sep 2023 to Sep 2024